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a b s t r a c t
Hemoglobin has been studied and well characterized in red blood cells for over 100 years. However, new
work has indicated that the hemoglobin α subunit (Hbα) is also found within the blood vessel wall,
where it appears to localize at the myoendothelial junction (MEJ) and plays a role in regulating nitric
oxide (NO) signaling between endothelium and smooth muscle. This discovery has created a new
paradigm for the control of endothelial nitric oxide synthase activity, nitric oxide diffusion, and,
ultimately, vascular tone and blood pressure. This review discusses the current knowledge of
hemoglobin's properties as a gas exchange molecule in the bloodstream and extrapolates the properties
of Hbα biology to the MEJ signaling domain. Speciﬁcally, we propose that Hbα is present at the MEJ to
regulate NO release and diffusion in a restricted physical space, which would have powerful implications
for the regulation of blood ﬂow in peripheral resistance arteries.
& 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Introduction
For over 100 years [1], hemoglobin has been known as the gas
exchange molecule found within red blood cells (RBCs) that is
responsible for delivering oxygen to tissues and subsequently remov-
ing carbon dioxide [2]. The structure of normal functional adult
hemoglobin (HbA; Fig. 1A) is composed of twin α and β globin
subunits (α2β2), each of which contains a heme, or iron ion, within a
heterocyclic ring of four pyrrole (C4H4NH) molecules known as a
porphyrin. The assembled tetramer can interact with the aforemen-
tioned gases, as well as carbon monoxide and nitric oxide (NO). Today,
this paradigm in RBCs remains unchanged. However we [3], and
others [4,5], have demonstrated that Hbα is expressed in the blood
vessel wall but, in contrast to other globins in the blood vessel wall
[3,6,7], Hbα localization and physiological effects are concentrated at
myoendothelial junctions (MEJs) in the endothelial cells (ECs) lining
the lumen of blood vessels.
Although the discovery of Hbα in the blood vessel wall is unique,
there have been clues from human diseases of Hbα deletion, possibly
independent of RBC function, that already indicated its possible
presence. The Hbα gene is located on chromosome 16 and has two
identical but duplicated coding sequences, HBA-1 and HBA-2. Genetic
deletion of or loss-of-function mutations in the Hbα alleles are known
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as α-thalassemia, a condition that is deﬁned by the severity of changes
to red blood cell indices [8,9]. Patients with αþ-thalassemia (silent
carriers) will have deletion of or loss-of-function mutation in one of
the HBA-1 or HBA-2 alleles. However, compensation enables them to
remain asymptomatic and many go undiagnosed. Deletion of two of
the HBA-1 and HBA-2 alleles causes α0-thalassemia, which presents
with moderate or severe RBC indices, depending on the deletion type
or mutation [9]. In terms of the vascular phenotype, this frequently
includes moderate hypotension. Deletion of three of the HBA-1 and
HBA-2 alleles is known as HbH disease and is characterized by
hemolytic anemia, hepatosplenomegaly, and the formation of a
tetramer of β chains in vivo. Owing to the severity of RBC indices, it
remains unclear if the vascular phenotype remains consistent with α0-
thalassemia or is hidden by development of other pathologies.
Hydrops fetalis syndrome (Hb Bart syndrome) occurs with deletion
of all of the Hbα alleles and results in death in utero [10]. The vascular
phenotype of dilated cerebral arteries is observed via ultrasound and
also is used to assist in the diagnosis of the disease although difﬁcult to
delineate from the accompanying severe anemia (Table 1) [11–15].
Regardless, this would correlate with observations from patients with
different degrees of Hgα deletion presenting with differences in
capillary diameter [16]. In each of these cases, a role for Hbα in RBCs
is challenging to fully explain the vascular phenotype presented.
However, reduction or deletion of Hbα in ECs of the resistance arteries,
where it is hypothesized to regulate NO delivery to vascular smooth
muscle cells (VSMCs), could be a reason. Future research in this area
could lead to important new insights into the pathology as well as
diagnosis related to these diseases.
Hemoglobin α, certae sedis
The ﬁrst evidence of localization and function for Hbα in the
blood vessel wall was seen in MEJs from resistance arteries in the
systemic vasculature [3]. Resistance arteries are the small arteries
that contribute the greatest amount to peripheral resistance and
thus overall blood pressure regulation [17,18]. In resistance vascu-
lature heterocellular communication is critical to the maintenance
of vascular tone and blood pressure (for review, see [19,20]).
Crucial to heterocellular communication in resistance arteries is
the presence of MEJs. The MEJ is the physical link between ECs and
VSMCs, characterized as a small protrusion of mostly ECs (approxi-
mately 0.5 μm wide and long) through the internal elastic lamina,
linking with VSMCs through gap junctions [12]. Myoendothelial
junctions are found throughout the vasculature; however, a
gradient is observed such that the junctions are more prevalent
as the diameter of the vascular tree decreases [21]. Thus, MEJs
represent the closest physical location of ECs to VSMCs in the
Fig. 1. Structure of Hbα. (A) HbA is a heterotetramer with two α subunits (gray) and two β subunits (purple). (B) Monomeric Hbα (rendered in cartoon) is stabilized by AHSP
(surface representation). The overall backbone fold of Hbα bound to AHSP (C and D, gray) is similar to Hbα (C, yellow) and Hbβ (D, orange) of HbA.
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Table 1
α-Thalassemias.
Chromosome 16 (both copies shown) Genotype RBC indices Vascular phenotype Classiﬁcation
HBZ HBA-2 HBA-1
¼¼¼ |ζ|¼¼¼¼¼¼¼¼ |α|¼¼¼¼¼¼¼¼¼¼¼¼¼ |α|¼¼¼¼ αα/αα Normal Normal Normal
¼¼¼ |ζ|¼¼¼¼¼¼¼¼ |α|¼¼¼¼¼¼¼¼¼¼¼¼¼ |α|¼¼¼¼
¼¼¼ |ζ|¼¼¼¼¼¼¼¼ |α|¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼ α/αα Normal Moderate hypotension
with potential compensation
α-Thalassemia minima, also
known as
heterozygosity for αþ-
thalassemia, silent
carrier of α-thalassemia, and
α-thalassemia-2 trait
¼¼¼ |ζ|¼¼¼¼¼¼¼¼ |α|¼¼¼¼¼¼¼¼¼¼¼¼¼ |α|¼¼¼¼
¼¼¼ |ζ|¼¼¼¼¼¼¼¼ |α|¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼ α/α or /αα Minimal anemia,
decreased MCV
and MCH
Moderate hypotension α-Thalassemia minor, also
known
as α-thalassemia-1 trait (due
to homozygosity
for αþ-thalassemia (α /α)
or heterozygosity
for α0-thalassemia (/αα))
¼¼¼ |ζ|¼¼¼¼¼¼¼¼ |α|¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼
or
¼¼¼ |ζ|¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼
¼¼¼ |ζ|¼¼¼¼¼¼¼¼ |α|¼¼¼¼¼¼¼¼¼¼¼¼¼ |α|¼¼¼¼
¼¼¼ |ζ|¼¼¼¼¼¼¼¼ |α|¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼ α/ Hemolytic anemia with the
formation of β-chain tetramers
None documented Hemoglobin H (HbH) disease
¼¼¼ |ζ|¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼
¼¼¼ |ζ|¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼ / Severe anemia due to
formation of γ4 tetramers
(hemoglobin Bart's)
Hydrops fetalis with
increased cerebral blood
ﬂow
Hydrops fetalis syndrome
with hemoglobin Bart's¼¼¼ |ζ|¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼¼
Chromosome 16 contains two identical coding sequences for hemoglobin α, hemoglobin α2 and hemoglobin α1 (shown here in reference to the ζ-globin gene, which is also located on chromosome 16). Deletions/nonfunctional
mutations are depicted by the absence of a corresponding box. Genotype, red blood cell (RBC) indices, vascular phenotype with relation to blood pressure, and medical classiﬁcation of the various α-thalassemia's are also listed
[8,10,44,74].
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small resistance arteries. The MEJ is acknowledged as an important
signaling microdomain (for review, see [22]) not only because of
its spatially limited structure, but also because the MEJ serves as
the gateway between EC signal transduction to the VSMC [22]. For
instance, S-nitrosylation/denitrosylation of connexin 43 is con-
trolled by speciﬁc proteins localized to the MEJ, including S-
nitrosoglutathione reductase (GSNOR), endothelial nitric oxide
synthase (eNOS), and IP3 receptor type 1 [23]. Together, these
proteins participate in localized signaling that promotes negative
feedback on vasoconstriction induced by α1-adrenergic receptor
activation. Importantly, whereas eNOS is localized to intracellular
regions including plasma membrane caveolae and the Golgi
complex, it is also localized to the MEJ [24,25]. Endothelial cells
exhibit a strict and varied control over the production of NO
(reviewed in [26]) and the predominant enzyme responsible for
the generation of NO in these cells is eNOS. This localization of
eNOS at the MEJ presumably occurs because NO is a highly
reactive gaseous free radical, enabling targeted release of NO at
proximal sites to the overlying VSMCs, where it functions as a
potent vasodilator. Subsequent work demonstrated that eNOS and
Hbα reside in close proximity to each other and potentially form a
macromolecular complex at the MEJ [3], where they provide a
regulatory mechanism for NO-mediated vasodilation (Fig. 2).
Three general outcomes await NO once it is produced in EC: it
can (1) diffuse into the bloodstream where it is rapidly scavenged,
ﬁrst by cell-free hemoglobin in the plasma and even further by
hemoglobin in RBCs [27]; (2) diffuse to neighboring VSMCs and
cause vasorelaxation; or (3) be scavenged by any number of
molecules, such as reactive oxygen species (ROS) (for review, see
[28]). In the bloodstream, most NO diffuses across its concentra-
tion gradient into RBCs, where it is either scavenged or stored. NO
scavenging proceeds via oxidation by oxyhemoglobin, which
produces methemoglobin and nitrate. This is the favored reaction;
however, NO can also bind directly to deoxygenated hemoglobin
in a simple addition reaction to form iron–nitrosyl–hemoglobin
[29]. Furthermore, it has been proposed that nitric oxide reacts in
an oxygen-sensitive mechanism with the conserved Cys93 residue
of the hemoglobin β-chain [30]; however, these ﬁndings have been
intensely debated [31–33]. Finally, data have suggested that eNOS is
present in RBCs [34], which possibly contributes to vasoprotectivity
[35–37]. Once in the VSMC, NO activates soluble guanylyl cyclase by
binding to its heme moiety, allowing a several hundredfold increase in
the catalysis of GTP to cGMP [38] and causing vasodilation through
several mechanisms [39]. Scavenging of NO occurs in pathologies that
result in, produce, or maintain elevated oxidant stress, especially when
accompanied by an inability to be counterbalanced by antioxidants.
Increased ROS can scavenge NO directly or alter pathways that
mediate NO production. The multiple fates of NO in the vasculature
are further complicated by its very short half-life (o5 s) [40].
Conceivably, in the ECs at the MEJ, any one of the above mechanisms
may be in play [41].
An important regulator in the binding of NO (and oxygen) to
hemoglobin is the oxidation state of the heme iron: ferrous (Fe2þ) or
ferric (Fe3þ). The ferric state of hemoglobin is also frequently known
as methemoglobin (MHb) [42,43]. However, the HbA in the blood-
stream contains less than 1% MHb because it possesses a higher
afﬁnity for oxygen and excess MHb can result in tissue hypoxia and
even death [44]. The oxidation state of iron also controls the sensitivity
of Hbα to NO; the Fe2þ state rapidly scavenges NO and the resulting
production of nitrate andmethemoglobin decreases NO bioavailability,
whereas the heme moiety in the Fe3þ state reacts slowly and
transiently with NO, allowing for increased diffusion of NO into
smooth muscle [45–47]. This reaction would presumably hold true
for the Hbα found in the MEJ. In RBCs, a methemoglobin reductase,
cytochrome b5 reductase 3 (CytB5R3, also known as diaphorase 1), is
present to recycle the Fe3þ state and prevent the accumulation of
MHb. When CytB5R3 is absent because of genetic defect or ingestion
of oxidizing toxins the resulting methemoglobinemia [48] (famously
characterized as a bluish tint to the skin) causes decreased tissue
oxygenation, hypoxia, and cyanosis [49]. Not surprisingly, the enzyme
CytB5R3 found in RBCs is also found in ECs and at the MEJ (although
not as strictly localized as Hbα). However, in contrast to the RBC in
which the Fe2þ oxidation state predominates, the MEJ heme moieties
in resistance arteries exist in both states (Fe3þ approximately 58%).
Knockdown of CytB5R3 reveals altered reactivity in ex vivo vessels to
adrenergic and endothelial-dependent NO stimulus, revealing a per-
missive effect of CytB5R3 on NO bioavailability [3]. Interestingly, the
CytB5R3 inhibitor and anti-thyroid drug propylthiouracil (PTU) also
presents with a reduction in blood pressure in rats [50]. This could be
explained by PTU preventing the CytB5R3 enzyme from reducing the
Fe3þ heme moieties in Hbα at the MEJ, thus maintaining the slower
NO-scavenging reaction and allowing for increased NO diffusion into
the VSMC. The evidence increasingly indicates that Hbα could play an
important role in regulating NO bioavailability through control of the
heme oxidation state.
Lastly, it is possible that Hbα is found in resistance arteries to
chelate excessive NO. This rationale is based on the fact that
conduit arteries have been previously characterized as largely
dependent on NO for vasodilator activity, whereas smaller resistance
Fig. 2. Schematic of NO regulation at the MEJ: negative feedback after α1-
adrenergic receptor-induced vasoconstriction at the myoendothelial junction
(MEJ) of an endothelial cell (EC). α1-Adrenergic receptor agonists cause an increase
in smooth muscle cell (SMC) cytosolic inositol 1,4,5-trisphosphate (IP3), which
travels down its concentration gradient through open (i.e., S-nitrosylated) connexin
43 (Cx43) channels. IP3 binds to localized IP3-receptor 1 on the endoplasmic
reticulum (not shown), which causes localized calcium (Ca2þ) release and an
increase in cytosolic Ca2þ concentration at the MEJ. This increase in cytosolic Ca2þ
facilitates activation of S-nitrosoglutathione reductase (GSNOR), which denitrosy-
lates and closes Cx43 channels, making them impermeable to IP3. The increase in
cytosolic Ca2þ also activates calmodulin (CaM) through binding-induced confor-
mational changes. The Ca2þ/CaM complex binds to endothelial nitric oxide
synthase (eNOS), facilitating its phosphorylation, activation, and production of
nitric oxide (NO). Some of this newly produced NO will diffuse into SMCs, where it
binds to and activates soluble guanylyl cyclase (sGC), facilitating the conversion of
GTP to cGMP, which ultimately leads to a reduction in constriction. The newly
produced NO may also facilitate opening of Cx43 channels through S-nitrosylation.
Finally, excess NO may be scavenged by free hemoglobin α (Hbα) at the MEJ
through reaction with oxyhemoglobin α (fast), or NO may be chelated through
reaction with methemoglobin α (slow). Cytochrome b5 reductase (CyB5R3) con-
verts methemoglobin α to Hbα, which readily binds oxygen [3,6,21–23].
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vessels rely on the action of endothelium-derived hyperpolarizing
factor (EDHF) [22,51]. However, there is no observable difference in
the total protein expression of eNOS in carotid and third-order
mesenteric arteries (i.e., resistance arteries; Fig. 3). Thus, Hbα at the
MEJ in resistance arteries may be chelating the NO generated by eNOS,
allowing for EDHF to remain dominant for increased endothelial-
dependent vasodilation, and maintaining strict control over NO for
other cellular functions (e.g., negative feedback after vasoconstriction).
It remains unclear how Hbα scavenges the excessive NO and whether
this action results in a permanent loss of NO or simply a reservoir of
NO that can be released upon appropriate stimulus. It is also possible
that the amount of eNOS between resistance arteries and conduit
arteries is inconsequential because the eNOS that is present in
resistance arteries is uncoupled compared to that in conduit arteries,
negating eNOS generation (e.g., [52,53]). It is unclear why such a
potent enzyme would still be present if this were the case; however,
the possibility exists and it is clear more work needs to be done in this
regard.
The importance of NO scavenging by Hbα at the MEJ is pre-
dominantly derived from its location. Nitric oxide scavenging by RBC
hemoglobin requires diffusion through the EC monolayer, the glyco-
calyx, and the plasma, and then NO interacts with cell-free hemo-
globin or must cross the RBC membrane before it reaches HbA. Based
on these assumptions, it is tempting to speculate that the likelihood
of locally produced NO at the MEJ interacting with Hbα is greatly
increased because of its proximity to the NO source. However, NO
produced on the luminal side of the endothelium would favor
scavenging by RBC hemoglobin. This implies that although the
relative abundance of Hb in RBCs may be greater, its importance
for the regulation of diffusion of NO into VSMCs may be reduced,
although this may change with deviation from basal conditions or
pathological states.
Why hemoglobin α in the endothelium?
One of the interesting questions that arises from the discovery
of Hbα at MEJs of ECs is, why Hbα, and not Hbβ? Wouldn't both
subunits be better than one for microcirculation where MEJs are
prevalent? As of yet there is no clear answer to this question.
Expression of both hemoglobin subunits has been reported in
many cell types beyond erythrocytes [54–59], which has sparked
hypotheses of functions in addition to oxygen transport and
delivery. The oxygen transport by Hb is speciﬁc to vertebrates,
with globins in other walks of life having a variety of functions
such as NO dioxygenase and peroxidase activity [60]. Individually,
the Hb subunits have damaging effects; thus, the assembly of HbA
is regulated. Only Hbα has a chaperone, α hemoglobin stabilizing
protein (AHSP), which maintains Hbα solubility and reduces
reactive oxygen species production by stabilizing the Fe3þ state
[61]. AHSP binds to Hbα in proximity to the Hbβ binding site
(Fig. 1B) and is displaced during the assembly of Hb. Therefore,
Hbα subunits may be considered the less toxic of the two subunits
for additional physiological roles owing to the added protection
of AHSP.
The Hbα and Hbβ subunits have very similar structures (Fig. 1C
and D) yet very different amino acid sequences (43% identity).
There are some structural rearrangements of Hbα upon binding
AHSP; however, the overall structure is very similar to both Hbα
and Hbβ in the heterotetramer. Both subunits similarly bind heme;
thus, in terms of oxygen binding and reactivity the subunits are
similar. However, the sequence differences between the subunits
could certainly provide differences in signaling. For instance, Hbα
molecular interactions that regulate NO signaling at the MEJ [3]
may be mediated by distinct amino acid regions of Hbα that are
different from Hbβ such that Hbβ would not elicit the same
signaling cascade. More work on this fundamental question will
certainly be required.
Vasculature effects of genetic hemoglobin deletion
In mice, similar to humans, deletion of all of the Hbα alleles is
lethal, making genetic studies on animals in vivo difﬁcult. How-
ever, there are other animal models found in nature in which Hbα
and Hbβ have been reported to be deleted, yet the animals still
prove viable, with very interesting effects on the vasculature
[62,63]. These animals, iceﬁshes (family Channichthyidae), dom-
inate the ﬁsh fauna of the Southern Ocean surrounding Antarctica
[64]. Iceﬁshes are exceptional in that they are the only known
vertebrate animals to completely lack the oxygen-carrier HbA in
their blood [65]. Loss of this key respiratory protein has produced
a phenotypically pale, translucent white blood and has earned
these animals the common names of “white-blooded ﬁshes” and
“iceﬁshes” (Fig. 4) [66]. Absent a gaseous transporter protein,
oxygen is carried unassisted in solution in iceﬁsh blood and results
in an oxygen-carrying capacity that is o10% of that exhibited by
red-blooded notothenioid ﬁshes [67]. Given this consequence and
the fact that the HbA-null condition proves lethal in all other
examples, both laboratory-based and natural, how has this
Fig. 4. Expression of eNOS between resistance and conduit arteries is equal.
Representative Western blot analysis of endothelial nitric oxide synthase (eNOS)
protein level in third-order mesenteric arteries compared to carotid. Samples were
equalized according to the amount of VE-cadherin, an endothelial cell marker.
Fig. 3. Blood from HbA and HbA-null ﬁsh. Blood samples from two Antarctic
notothenioid ﬁshes illustrate a striking contrast in the level of hemoglobin
expression. The test tube on the right contains blood from an HbA-expressing
species, Notothenia coriiceps, and the tube on the left depicts the completely HbA-
null phenotype of the “crocodile” iceﬁsh, Chaenocephalus aceratus.
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condition persisted in iceﬁshes? Although more complex and
beyond the scope of what we can present here (for an excellent
review, see [68]), there are several basic considerations that help
to answer this question. First, iceﬁshes possess cardiovascular
systems with unusually enhanced features compared to their
red-blooded notothenioid relatives; large hearts, large-diameter
capillaries, and large blood volumes collectively enable iceﬁshes to
maintain a high-throughput circulatory design without excessive
pressure development [69,70]. Combined with the abundantly
high oxygen content of Antarctic waters and their relatively low
metabolic rates, these cardiovascular traits permit iceﬁshes to
sufﬁciently oxygenate their tissues and support their aerobic mode
of metabolism [71]. As one might expect, however, the loss of
expression of HbA has implications for the metabolism of NO. It
was proposed that the loss of NO-oxygenase activity with genetic
deletion of HbA may have led to subsequent elevation of NO levels
that could explain many, if not all, of the unique cardiovascular
and physiological traits that evolved in iceﬁshes [68]. Substantiat-
ing at least part of that hypothesis, Beers et al. [72] established
that NO concentrations in blood plasma appear to be greater in
iceﬁshes than in HbA-expressing species. They also reported that
the high NO levels in iceﬁshes were not the result of greater
synthesis but, rather, appeared to be due primarily to the loss of
the degradative pathway for NO [72].
Building upon the above work, Borley and collaborators [73]
subsequently conducted a study in which they induced severe
anemia in Notothenia coriiceps, an HbA-expressing notothenioid
with a normal hematocrit of 35–40%. Surgically implanted osmotic
pumps were used to treat individuals with a powerful hemolytic
agent that resulted in a drastic reduction in hematocrit (490%)
and HbA concentration (470%). Levels of NO were signiﬁcantly
higher in anemic animals compared to the full HbA-expressing
controls and were similar to the levels of NO reported for white-
blooded iceﬁshes [72,73]. Although MEJs have not been identiﬁed
in these ﬁsh, it would be surprising if these anatomical structures
were not present. The regulation of NO in the arteries of iceﬁsh
could be one potential avenue for understanding how Hbα
regulates NO delivery in arteries with an in vivo model capable
of withstanding severe hemoglobin depletion.
Summary
This review describes a new paradigm of localized NO regula-
tion by Hbα in MEJs of resistance arteries. This unique micro-
domain has the potential for pharmacological targeting and serves
as an explanation for several different pathologies associated with
Hbα deletion. Although some investigation into this observation
has been done, there is still much to do and we look forward to
extending this review in the future.
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